Table 1 Principal characteristics of included articles using QA tools in vitro SRs/MAs
From: Quality assessment tools used in systematic reviews of in vitro studies: A systematic review
Characteristics | Categorization | All studies (N = 244) |
|---|---|---|
Year of publication | 2007–2014 | 24 (9.8%) |
2015–2020 | 220 (90.2%) | |
Region | Europe | 99 (40.6%) |
South-America | 64 (26.2%) | |
Asia | 33 (13.5%) | |
Middle East | 26 (10.7%) | |
North America | 14 (5.7%) | |
Australia | 5 (2%) | |
Africa | 3 (1.2%) | |
Study topic | Dentistry | 125 (51.2%) |
Bioactivity | 53 (21.7%) | |
Biology | 31 (12.7%) | |
Methodology | 13 (5.3%) | |
Materials | 9 (3.7%) | |
Pharmacology | 5 (2%) | |
Diagnosis | 4 (1.6%) | |
Toxicity | 4 (1.6%) | |
Reporting QA used | PRISMA | 143 (58.6%) |
N | 93 (38.1%) | |
PRISMA and AMSTAR | 3 (1.3%) | |
Cochrane Handbook for Systematic Reviews of Interventions | 2 (0.8%) | |
STROBE | 1 (0.4%) | |
QUOROM | 1 (0.4%) | |
OHAT | 1 (0.4%) | |
QA used | Y | 126 (51.6%) |
N | 118 (48.4%) | |
Conducting meta-analysis | Y | 71 (29.1%) |
N | 173 (70.9%) | |
QA tool used | NR | 120 (49.2%) |
Following previous description of Onofre et al. | 29 (11.9%) | |
Developed by authors | 28 (11.5%) | |
Cochrane Risk of Bias tool | 12 (4.9%) | |
CONSORT | 8 (3.3%) | |
ToxRTool | 5 (2%) | |
OHAT | 4 (1.6%) | |
Joanna Briggs Institute Clinical Appraisal Checklist | 4 (1.6%) | |
MINORS | 4 (1.6%) | |
QUADAS-2 | 4 (1.6%) | |
GRADE | 3 (1.2%) | |
NOS | 3 (1.2%) | |
Following previous description of Onofre et al. and Montagner et al. | 2 (0.8%) | |
STROBE | 2 (0.8%) | |
Following the previous description of Bader et al | 1 (0.4%) | |
Following previous description of Sackett et al | 1 (0.4%) | |
JADAD | 1 (0.4%) | |
SciRAP method | 1 (0.4%) | |
CASP and MINORS | 1 (0.4%) | |
Timmer’s Analysis Tool | 1 (0.4%) | |
ARRIVE | 1 (0.4%) | |
QUADAS | 1 (0.4%) | |
Modifying Quality Assessment Tool for Studies with Diverse Designs (QATSDD) | 1 (0.4%) | |
Referencing CRH and the EBM Evidence Pyramid | 1 (0.4%) | |
Nature Publication Quality Improvement Project (NPQIP) study | 1 (0.4%) | |
Standard Quality Assessment Criteria for Evaluating Primary Research Papers from a Variety of Fields | 1 (0.4%) | |
Following previous description of Samuel et al. | 1 (0.4%) | |
SYCLE | 1 (0.4%) | |
World Cancer Research Fund/ University of Bristol for cell line | 1 (0.4%) | |
CRIS guidelines | 1 (0.4%) | |
Following Joanna Briggs Institute Clinical Appraisal Checklist for Experimental Studies | 1 (0.4%) | |
PRISMA | 1 (0.4%) | |
Downs and Black | 1 (0.4%) |